Deciphering the Dynamics of EGFR-TKI Resistance in Lung Cancer: Insights from Bibliometric Analysis
Yinxue Zhou,Tingyu Wu,Jiaxing Sun,Huanhuan Bi,Yuting Xiao,Yanmei Shao,Weizhong Han,Hongmei Wang
DOI: https://doi.org/10.2147/dddt.s478910
IF: 4.3188
2024-09-27
Drug Design Development and Therapy
Abstract:Yinxue Zhou, 1, &ast Tingyu Wu, 2, &ast Jiaxing Sun, 1 Huanhuan Bi, 1 Yuting Xiao, 1 Yanmei Shao, 1 Weizhong Han, 1 Hongmei Wang 1 1 Department of Respiratory and Critical Care Medicine, The Affiliated Hospital of Qingdao University, Qingdao, People's Republic of China; 2 Department of Joint Surgery, The Affiliated Hospital of Qingdao University, Qingdao, People's Republic of China &astThese authors contributed equally to this work Correspondence: Jiaxing Sun; Hongmei Wang, Email ; Background: EGFR-TKI resistance poses a significant challenge in the treatment landscape of non-small cell lung cancer (NSCLC), prompting extensive research into mechanisms and therapeutic strategies. In this study, we conduct a bibliometric analysis to elucidate evolving research hotspots and trends in EGFR-TKI resistance, offering insights for clinical interventions and scientific inquiries. Methods: Publications spanning from 1996 to 2024, focusing on EGFR-TKI resistance in NSCLC, were sourced from the Web of Science Core Collection. Utilizing VOSviewer 1.6.19, CiteSpace 6.2. R2, and Scimago Graphica 1.0.35, we analyzed these articles to identify countries/regions and institutions, Journals, publications, key contributors, collaborations, and emerging topics. Results: An analysis of 8051 articles by 38,215 researchers from 86 countries shows growing interest in EGFR-TKI resistance mechanisms. Since 1996, publications have steadily increased, surpassing 500 per year after 2016, with a sharp rise in citations. Research articles make up 84% of publications, emphasizing scholarly focus. Global collaboration, especially among researchers in China, the US, and Japan, is strong. Leading institutions like Dana-Farber and Harvard, along with journals such as "Lung Cancer", are key in sharing findings. Professors Yi-Long Wu and William Pao are prominent contributors. Keyword analysis reveals core themes, including first-generation EGFR-TKIs, emerging agents like osimertinib, and research on the T790M mutation. Conclusion: EGFR-TKI resistance remains a critical issue in NSCLC treatment, driving ongoing research efforts worldwide. Focusing future research on clear identification of resistance mechanisms will guide post-resistance treatment strategies, necessitating further exploration, alongside the validation of emerging drugs through clinical trials. Moreover, "chemo+" treatments following EGFR-TKI resistance require more clinical data and real-world evidence for assessing safety and patient outcomes. As research advances, a multidisciplinary approach will be key to overcoming these challenges. Continued innovation in treatment could greatly enhance patient survival and quality of life. Keywords: EGFR-TKI, resistance, lung cancer, bibliometric, citespace, VOSviewer In April 2024, the World Health Organization reported that in 2022, there were 19.965 million new cancer cases and 9.737 million cancer-related deaths worldwide. Lung cancer was the most common, with 2.48 million cases, making up 12.4% of the total. Data from the International Agency for Research on Cancer (IARC) shows that lung cancer is one of the leading causes of cancer deaths globally, accounting for 20.4% of cancer deaths in the US in 2024, with around 343 daily fatalities. Among early-stage lung cancer patients, EGFR mutations are the most frequent, found in 56% of cases. 1 Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have revolutionized the treatment landscape of non-small cell lung cancer (NSCLC), particularly in patients harboring EGFR mutations. EGFR mutations, present in approximately 50% of lung adenocarcinomas, 2 are pivotal in driving tumorigenesis by activating downstream signaling pathways involved in cell proliferation and survival. 3 Compared to Western populations, the EGFR mutation rate is significantly higher in Asians, detected in over 50% of advanced lung adenocarcinoma cases, and is considered a "golden mutation" in this group. 4 The advent of EGFR-TKIs, such as gefitinib, erlotinib, afatinib, and Osimertinib, marked a paradigm shift in NSCLC treatment, offering targeted therapy tailored to the molecular profile of the tumor. Nevertheless, after 9–13 months of first- and second-generation EGFR-TKI treatment, acquired resistance inevitably develops through various mechanisms, with the T790M mutation in exon 20 being the primary cause, occurring in 50–60% of patients. 5–7 Intrinsic resistance, often attributed to primary mutations like T790M, limits the initial response to EGFR-TKIs. Acquired resistance, on the other hand, manifests through secondary mu -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal